Ibogaine, a powerful psychedelic substance, is drawing new interest from officials in the Trump administration as a possible treatment option, according to reporting from CNN published May 10. The renewed attention marks a notable shift for a drug long kept at the margins of medical practice.
CNN reports that senior administration figures have recently discussed ibogaine in the context of potential therapeutic use, including for difficult-to-treat conditions. The substance remains illegal at the federal level and is classified as a Schedule I drug in the United States, meaning it is considered to have a high potential for abuse and no accepted medical use under current law.
What is driving the new interest
According to CNN’s account, ibogaine has come under review as part of a broader look at psychedelic compounds as possible medical tools. Within that discussion, administration officials have shown particular interest in whether ibogaine could be evaluated as a treatment option under existing U.S. regulatory pathways.
The reporting indicates that this interest is at an early stage. CNN describes internal conversations about ibogaine’s potential but does not detail any formal policy change, clinical program, or federal funding decision tied to the drug.
Role of federal regulators
CNN’s reporting places the Food and Drug Administration (FDA) in the frame as a key institution for any future steps. Because ibogaine is a controlled substance, any move toward medical use in the United States would require FDA oversight of safety and efficacy data, along with coordination on drug scheduling.
At this stage, CNN does not describe a specific FDA decision or new ibogaine approval process. Instead, the network’s account underscores that regulators would have to be involved if the administration chose to support clinical research or consider therapeutic use.
International dimension and Iran reference
CNN’s report links the ibogaine discussions to wider policy considerations that include international security and diplomacy. Within that context, the reporting names Iran among the countries that could be affected as the situation develops.
The network does not provide detailed public documentation of how ibogaine policy discussions intersect with Iran specifically. CNN’s framing suggests that any change in U.S. posture toward psychedelic drugs, including ibogaine, could carry implications beyond domestic health policy, potentially touching on international relationships and security concerns.
Limited independent corroboration
CNN is currently the primary outlet describing this new wave of interest in ibogaine inside the Trump administration. The available reporting notes that independent corroboration of the internal discussions is limited in this news cycle and should be monitored as additional information emerges.
That constraint means key elements of the story—such as which specific officials are leading the ibogaine review and what formal steps, if any, have been initiated—remain only partially documented in public. CNN’s account provides the main description of the administration’s posture so far.
Why this development matters
If the interest described by CNN leads to concrete action, ibogaine could move from the fringes of medicine toward formal evaluation in U.S. regulatory channels. That would represent a significant change for a Schedule I psychedelic.
Because CNN also links the discussions to broader security and diplomatic considerations involving countries such as Iran, any shift in U.S. policy on ibogaine could have consequences beyond health care. For now, the key facts are that Trump administration officials are newly focused on ibogaine as a potential treatment option, the FDA would be central to any next steps, and independent confirmation of the internal talks remains limited.
Readers should watch for further disclosures from federal agencies, additional on-the-record statements from administration officials, and corroborating reports from other news organizations to clarify how far these ibogaine discussions will go and whether they translate into formal policy or regulatory action.
